Pharma bosses faced a grilling from the US Senate’s Finance Committee over the high price of branded prescription drugs in the US compared with other developed countries.
AbbVie has extended its collaboration with gene therapy specialist Voyager Therapeutics, adding a new programme in Parkinson’s disease and another $1.5 billion in potential fees.
With a Brexit deal still out of sight, there have been intensified warnings in the UK about potential disruptions to medicine supplies that could follow a no-deal scenario.
Pfizer is moving rheumatoid arthritis patients to a lower dose of its blockbuster inflammatory diseases pill Xeljanz in a clinical study, after a safety signal emerged in the trial of patie
AbbVie’s attempts to diversify beyond Humira have been boosted as its investigational drug upadacitinib has been granted Priority Review by the FDA for moder
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
